In plain words
Two placebo-controlled trials, one of 150 adults taking 120 mg a day for six weeks and one of 80 people over eight weeks (the ledger has no dose for the second), both found better sleep in the groups taking ashwagandha. In the smaller trial the gain was larger in people with insomnia.
The short answer
Both randomized trials in the ledger found better sleep with ashwagandha than with placebo. Deshpande and colleagues (2020) gave 150 healthy adults with non-restorative sleep 120 mg a day for six weeks; self-reported sleep quality rose 72%, against 29% on placebo. Langade and colleagues (2020) found improved sleep measures in 80 healthy and insomnia participants over eight weeks, more so with insomnia; the ledger has no dose for this trial. Two meta-analyses (2021, 2025) report pooled gains that may include these trials, so they add no separate evidence. Certainty is low, because the two trials are short and small, and the ledger has no funding for either.
Where the evidence sits
Sleep improved
■ measured by the source's own study · ◪ pooled analysis, may overlap studies counted here · □ reported, reviewed or argued, no new data
Who says what
| Source | Finding | Design | People | Dose and length | Funding and independence |
|---|---|---|---|---|---|
| Deshpande et al., 2020 | Sleep quality up 72% vs 29% on placebo | Randomized, placebo-controlled | 150 adults, non-restorative sleep | 120 mg daily, 6 weeks | Not in ledger |
| Langade et al., 2020 | Sleep improved, more with insomnia | Randomized, placebo-controlled | 80, healthy and insomnia | Dose not in ledger; 8 weeks | Not in ledger |
| Cheah et al., 2021 | Small overall gain; no significant Pittsburgh index difference | Meta-analysis that may include the trials above | 400 | 120 to 600 mg daily, 6 to 12 weeks | Not in ledger |
| BJPsych Open meta-analysis, 2025 | Pooled sleep quality gain | Meta-analysis that may include the trials above | Not in ledger | Not in ledger | Not in ledger |
| NCCIH (NIH), 2023 | Some preparations may help insomnia | Government agency summarizing research | None | Not in ledger | NIH agency |
Sleep quality up 72% vs 29% on placebo
Sleep improved, more with insomnia
Small overall gain; no significant Pittsburgh index difference
Pooled sleep quality gain
Some preparations may help insomnia
What did the two trials find?
Deshpande and colleagues (2020) gave 150 healthy adults with non-restorative sleep 120 mg of extract or placebo daily for six weeks; 144 finished, with no dropouts due to adverse events. They report self-reported sleep quality:
A 72% increase in self-reported sleep quality was found for the treatment group, compared with 29% in the placebo group (p < 0.001).
Activity monitors in the same trial showed improved sleep efficiency, total sleep time, time to fall asleep and time awake at night against placebo.
Langade and colleagues (2020) tested root extract against placebo for eight weeks in 80 healthy and insomnia participants; the ledger has no dose for this trial. Time to fall asleep and sleep efficiency improved most, and the authors compared the two groups:
The improvement was found more significant in insomnia subjects than healthy subjects.
What do the pooled analyses add?
Cheah and colleagues (2021) pooled five randomized studies with 400 participants at 120 to 600 mg a day for 6 to 12 weeks, a pooled estimate that may include the trials above. It found a small gain in overall sleep but no significant difference on the Pittsburgh Sleep Quality Index in a subset of 131 participants, for which the ledger has no dose or duration. The review also looked at subgroups:
The effects on sleep were more prominent in the subgroup of adults diagnosed with insomnia, treatment dosage ≥600 mg/day, and treatment duration ≥8 weeks.
It reported no serious adverse effects in any pooled study. A 2025 BJPsych Open meta-analysis also pooled a sleep quality gain that may include the trials above; the ledger has no n, dose or duration for it. NCCIH (2023), an NIH agency summarizing research, writes that some preparations "may be effective for insomnia".
Why the sources disagree
No two measurements in the ledger contradict each other on sleep. The split is between measures: inside Cheah and colleagues' (2021) review, a pooled estimate that may include the trials above found a small overall gain but no significant Pittsburgh index difference. The trials also differ in people and dose: 150 adults with non-restorative sleep at 120 mg a day for six weeks, against 80 healthy and insomnia participants for eight weeks with no dose in the ledger. The ledger has no funding for any study.
What would settle it
An independently funded, pre-registered trial randomizing adults with diagnosed insomnia and healthy poor sleepers to 120 mg, 600 mg or placebo daily for 12 weeks, reporting the Pittsburgh Sleep Quality Index and activity-monitor sleep against placebo, with a check four weeks after stopping. A matching result from a second research group would raise certainty from low to moderate.
How this page was made
The 5 sources are two randomized trials and two meta-analyses, each a pooled estimate that may include the trials above, from a PubMed literature check, plus the NCCIH fact sheet; rodent studies and disease populations were left out. Every claim was copied word for word from its source into the Longevity Circle ledger and checked against the original text, and a person approved each one. Certainty follows the GRADE levels used in medical reviews. Drafting was assisted by AI.
Changelog: 25 Sep 2026, first version, 5 sources.
